Melbourne, Australia; 10 October, 2013: Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that results related to its novel anti-cancer PAT-SM6 lead clinical candidate and data generated to date from the ongoing clinical trial in multiple myeloma has been accepted for presentation at the 55th ASH Annual Meeting and Exposition, run by the American Society of Hematology in New Orleans, to be held on 7- 10 December 2013.
I get the feeling we are going to receive a lot more attention at this conference,than originally now we onyx associated with us.
onyx, page-7
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 4291214 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 600160 | 2 |
View Market Depth
| Last trade - 16.12pm 09/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable